In an interview with Technology Networks, Dr. Daniel Reker discusses how machine learning is improving data-scarce areas of ...

In the pursuit of solutions to complex global challenges including disease, energy demands, and climate change, scientific ...

Advancing proprietary AI discovery of high-bioavailability Oral GLP-1 drug candidates. HOUSTON, Feb. 3, 2026 /PRNewswire/ -- Deep EigenMatics, Inc., a pioneer in high-velocity Artificial Intelligence ...

The global artificial intelligence (AI) in drug discovery market is experiencing rapid expansion, driven by the need to reduce the high costs and long timelines of traditional pharmaceutical ...

In the pursuit of solutions to complex global challenges including disease, energy demands, and climate change, scientific ...

AI has fundamentally altered the feasibility of natural product discovery from fungal endophytes. Advances in genome sequencing, metabolomics, and systems biology have generated vast datasets, but ...

LIGAND-AI is a flagship project of the Target 2035 initiative, funded by the Innovative Health Initiative, a public-private partnership (PPP) between the European Union and the European life science ...

Explore the complexities of tauopathies and how new research could change their diagnosis and treatment approaches.

Discover how researchers are overcoming the limitations of the undruggable target in drug discovery using novel approaches ...

At Web Summit Qatar, AI-powered biotech startups describe how automation, data, and gene editing are filling labor gaps in ...

Biomedicines is the latest biotech to mull going public as momentum for IPOs continues to build. | Clinical-stage antibody company Generate:Biomedicines is the latest biotech to mull going public as ...

How Isomorphic Labs Is Rewriting Drug Discovery. Google DeepMind spin-off Isomorphic Labs is building an AI drug design engine that it believes can“solve” all diseases. We spoke to its Chief Technolog ...